Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLF31907 in advanced melanoma and urothelial carcinoma
NCT05823246Phase 2Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2023
- Primary completion
- Oct 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QLF31907 in melanoma, urothelial carcinoma (UC), sponsored by Qilu Pharmaceutical. Status: unknown.
02
Drugs
QLF31907
03
Conditions
melanomaurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05823246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823246.